Loss of LRIG1 locus increases risk of early and late relapse of stage I/II breast cancer

Cancer Research

Volumn 74, Issue 11, 2014, Pages 2928-2935

  Thompson, Patricia A ^a   Ljuslinder, Ingrid ^d   Tsavachidis, Spyros ^b   Brewster, Abenaa ^c   Sahin, Aysegul ^c   Hedman, Håkan ^d   Henriksson, Roger ^d   Bondy, Melissa L ^b   Melin, Beatrice S ^d  

^a UNIVERSITY OF ARIZONA   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d UMEÅ UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CHROMOSOME 3; CHROMOSOME HIGH RESOLUTION BANDING ANALYSIS; CONTROLLED STUDY; COPY NUMBER VARIATION; DISTANT METASTASIS FREE SURVIVAL; ETHNICITY; FEMALE; GAIN OF FUNCTION MUTATION; GENE; GENE EXPRESSION; GENE FUNCTION; GENE LOCUS; GENE LOSS; GENE PROBE; GENETIC ASSOCIATION; HIGH RISK PATIENT; HUMAN; LOSS OF FUNCTION MUTATION; LRIG1 GENE; MAJOR CLINICAL STUDY; MUTATIONAL ANALYSIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; RECURRENCE RISK; TUMOR VOLUME; BREAST TUMOR; CASE CONTROL STUDY; GENE DOSAGE; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; PATHOLOGY; TUMOR RECURRENCE;

LRIG1 PROTEIN, HUMAN; MEMBRANE PROTEIN;

BREAST NEOPLASMS; CASE-CONTROL STUDIES; CHROMOSOMES, HUMAN, PAIR 3; FEMALE; GENE DOSAGE; GENE EXPRESSION; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING;

EID: 84902175780     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-2112     Document Type: Article

References (19)

1. Nilsson J, Vallbo C, Guo D, Golovleva I, Hallberg B, Henriksson R, et al. Cloning, characterization, and expression of human LIG1. Biochem Biophys Res Commun 2001;284:1155-61.
2. Gur G, Rubin C, Katz M, Amit I, Citri A, Nilsson J, et al. LRIG1 restricts growth factor signaling by enhancing receptor ubiquitylation and degradation. EMBO J 2004;23:3270-81.
3. Laederich MB, Funes-Duran M, Yen L, Ingalla E, Wu X, Carraway KL3rd, et al. The leucine-rich repeat protein LRIG1 is a negative regulator of ErbB family receptor tyrosine kinases. J Biol Chem 2004; 279:47050-6.
4. Miller JK, Shattuck DL, Ingalla EQ, Yen L, Borowsky AD, Young LJ, et al. Suppression of the negative regulator LRIG1 contributes to ErbB2 overexpression in breast cancer. Cancer Res 2008;68: 8286-94.
5. Ledda F, Bieraugel O, Fard SS, Vilar M, Paratcha G. LRIG1 is an endogenous inhibitor of Ret receptor tyrosine kinase activation, downstream signaling, and biological responses to GDNF. J Neurosci 2008;28:39-49.
6. Nilsson J, Starefeldt A, Henriksson R, Hedman H. LRIG1 protein in human cells and tissues. Cell Tissue Res 2003;312:65-71.
7. Wong VW, Stange DE, Page ME, Buczacki S, Wabik A, Itami S, et al. LRIG1controls intestinal stem-cell homeostasis by negative regulation of ErbB signalling. Nat Cell Biol 2012;14:401-8.
8. Powell AE, Wang Y, Li Y, Poulin EJ, Means AL, Washington MK, et al. The pan-ErbB negative regulator LRIG1 is an intestinal stem cell marker that functions as a tumor suppressor. Cell 2012;149:146-58.
9. Ordonez-Moran P, Huelsken J. LRIG1: A new master regulator of epithelial stem cells. EMBO J 2012;31:2064-6.
10. Jensen KB, Collins CA, Nascimento E, Tan DW, Frye M, Itami S, et al. LRIG1 expression defines a distinct multipotent stem cell population in mammalian epidermis. Cell Stem Cell 2009;4:427-39.
11. Suzuki Y, Miura H, Tanemura A, Kobayashi K, Kondoh G, Sano S, et al. Targeted disruption of LIG-1 gene results in psoriasiform epidermal hyperplasia. FEBS Lett 2002;521:67-71.
12. Ljuslinder I, Malmer B, Golovleva I, Thomasson M, Grankvist K, Hockenstrom T, et al. Increased copy number at 3p14 in breast cancer. Breast Cancer Res 2005;7:R719-27.
13. Ljuslinder I, Golovleva I, HenrikssonR, Grankvist K, MalmerB, Hedman H. Co-incidental increase in gene copy number of ERBB2 and LRIG1 in breast cancer. Breast Cancer Res 2009;11:403.
14. Krig SR, Frietze S, Simion C, Miller JK, Fry WHD, Rafidi H, et al. LRIG1 is an estrogen-regulated growth suppressor and correlates with longer relapse-free survival in ER^I-positive breast cancer. Mol Cancer Res 2011;9:1406-17.
15. Staaf J, Jonsson G, Ringner M, Vallon-Christersson J, Grabau D, Arason A, et al. High-resolution genomic and expression analyses of copy number alterations in HER2-amplified breast cancer. Breast Cancer Res 2012;12:R25.
16. Brewster AM, Do KA, Thompson PA, Hahn KM, Sahin AA, Cao Y, et al. Relationship between epidemiologic risk factors and breast cancer recurrence. J Clin Oncol 2007;25:4438-44.
17. Thompson PA, Brewster AM, Kim-Anh D, Baladandayuthapani V, Broom BM, Edgerton ME, et al. Selective genomic copy number imbalances and probability of recurrence in early-stage breast cancer. PLoS ONE 2011;6:e23543.
18. Pekarsky Y, Palamarchuk A, Huebner K, Croce CM. FHIT as tumor suppressor: mechanisms and therapeutic opportunities. Cancer Biol Ther 2002;1:232-6.
19. Ginestier C, Bardou V-J, Popovici C, Charafe-Jauffret E, Bertucci F, Geneix J, et al. Loss of FHIT protein expression is a marker of adverse evolution in good prognosis localized breast cancer. Int J Cancer 2003;107:854-62.